Subscribe to our RSS feeds RSS | Login | Register  
 

Washington Insider Articles

Industry-sponsored trials reach record high in '07

James G. Dickinson July 14, 2008

The number of new industry-sponsored clinical trial starts went up 12% to a record high in 2007, according to data released by Parexel International Corp.
 

FDA doesn't approve most generics reviewed in first cycle

James G. Dickinson July 14, 2008

An HHS Office of Inspector General report says the FDA does not approve 96% of new generic drugs reviewed during their first cycle because they contain chemistry deficiencies.
 

DDMAC responds to queries

James G. Dickinson July 14, 2008

DDMAC responses to queries posed by drug sponsors or manufacturers regarding ad/promo issues may only be regarded as official (for legal purposes) if they are received in letter form, the division's director, Thomas Abrams says.
 

Court limits False Claims Act liability for whistleblowers

James G. Dickinson July 14, 2008

In a ruling that provided comfort to drug companies defending dissident former employees' whistleblower suits, the US Supreme Court said in June that False Claims Act liability is limited to acts done with an intent that the government itself pay a false claim.
 

Amid high praise, FDA's top cop quits

James G. Dickinson July 14, 2008

Calling it "a tremendous loss for the agency," FDA commissioner Andrew von Eschenbach announced in June that the impending departure after three years in the job of the agency's top enforcement officer.
 

Drug company outsource probe sought

James G. Dickinson July 14, 2008

Sen. Sherrod Brown (D-OH) wants the FDA to evaluate how it protects the American public from drug products containing tainted, outsourced ingredients.
 

Kweder: new law slows down FDA approvals

James G. Dickinson July 14, 2008

While it holds exciting promise for protecting public health, last year's FDA Amendments Act (FDAAA) is actually slowing down new drug approvals, a key agency official warned in June.
 

As I see it

James G. Dickinson July 14, 2008

As a new study finds that pharma has become Washington's largest lobby in terms of dollars spent in campaign contributions, a high-stakes battle is looming in the heat of election season over what those dollars can buy—defeat of new advertising curbs, blockage of drug imports from Canada and Mexico, stronger patent protections and more.
 

FDA's 'Sentinental Initiative' to improve product safety

James G. Dickinson July 01, 2008

The FDA says it is undertaking a new initiative to develop a system to query a broad range of databases to identify possible post-marketing adverse events.
 

Woodcock takes GMO to the next level

James G. Dickinson July 01, 2008

The FDA's director of drugs, Janet Woodcock, is pushing her manufacturing and product quality experts to "reinvigorate" her brainchild "GMPs (Good Manufacturing Practices) for 21st Century" initiative and move it to the next level.
 
 
A Haymarket Media, Inc website
Home | News | Features | Events | Surveys | Lists | Directories | Jobs | About Us | Contact Us | Subscribe | Newsletters | PMD | Advertise | Editorial Advisory Board | Subscribe to our RSS feeds RSS

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions